First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties

OBJECTIVE: Upacicalcet is a new renally excreted and injectable calcimimetic agent. We evaluated the pharmacokinetics, pharmacodynamics, safety, and tolerability of single and multiple intravenous administration of upacicalcet in patients with secondary hyperparathyroidism undergoing hemodialysis. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazama, Junichiro James, Koiwa, Fumihiko, Yokoyama, Keitaro, Fukagawa, Masafumi, Asano, Kenji, Honda, Daisuke, Akizawa, Tadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439990/
https://www.ncbi.nlm.nih.gov/pubmed/35763247
http://dx.doi.org/10.1007/s40262-022-01139-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439990/
https://www.ncbi.nlm.nih.gov/pubmed/35763247
http://dx.doi.org/10.1007/s40262-022-01139-w

Ejemplares similares